AKT1 and glioma: Mechanistic investigation showed that LINC01426 exhibited its tumor promoter role by modulating the PI3K/Akt signaling pathway (Wang et al., 2018) and PI3K has been shown to be targeted therapy for glioma (Cruceru et al., 2013).